• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PATHWEIGH 研究的基线特征:初级保健中体重管理的阶梯式楔形群随机研究。

Baseline Characteristics of PATHWEIGH: A Stepped-Wedge Cluster Randomized Study for Weight Management in Primary Care.

机构信息

Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado

Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado.

出版信息

Ann Fam Med. 2023 May-Jun;21(3):249-255. doi: 10.1370/afm.2966.

DOI:10.1370/afm.2966
PMID:37217322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10202506/
Abstract

PURPOSE

To describe the characteristics of patients and practice of clinicians during standard-of-care for weight management in a large, multiclinic health system before the implementation of PATHWEIGH, a pragmatic weight management intervention.

METHODS

We analyzed baseline characteristics of patients, clinicians, and clinics during standard-of-care for weight management before the implementation of PATHWEIGH, which will be evaluated for effectiveness and implementation in primary care using an effectiveness-implementation hybrid type-1 cluster randomized stepped-wedge clinical trial design. A total of 57 primary care clinics were enrolled and randomized to 3 sequences. Patients included in the analysis met the eligibility requirements of age ≥18 years and body mass index (BMI) ≥25 kg/m and had a weight-prioritized visit (defined a priori) during the period March 17, 2020 to March 16, 2021.

RESULTS

A total of 12% of patients aged ≥18 years and with a BMI ≥25 kg/m seen in the 57 practices during the baseline period (n = 20,383) had a weight-prioritized visit. The 3 randomization sequences of 20, 18, and 19 sites were similar, with an overall mean patient age of 52 (SD 16) years, 58% women, 76% non-Hispanic White patients, 64% with commercial insurance, and with a mean BMI of 37 (SD 7) kg/m. Documented referral for anything weight related was low (<6%), and 334 prescriptions of an antiobesity drug were noted.

CONCLUSIONS

Of patients aged ≥18 years and with a BMI ≥25 kg/m in a large health system, 12% had a weight-prioritized visit during the baseline period. Despite most patients being commercially insured, referral to any weight-related service or prescription of antiobesity drug was uncommon. These results fortify the rationale for trying to improve weight management in primary care.

摘要

目的

在实施实用体重管理干预措施 PATHWEIGH 之前,描述在大型多诊所医疗系统中标准体重管理护理下患者的特征和临床医生的实践情况。

方法

我们分析了 PATHWEIGH 实施前标准体重管理护理期间患者、临床医生和诊所的基线特征,将使用有效性-实施混合 1 型聚类随机阶梯式临床试验设计评估其在初级保健中的效果和实施情况。共纳入 57 家初级保健诊所,并按 3 个序列进行随机分组。符合纳入标准的患者年龄≥18 岁,体重指数(BMI)≥25kg/m²,并在 2020 年 3 月 17 日至 2021 年 3 月 16 日期间进行了以体重为重点的就诊(预先定义)。

结果

在基线期 57 家诊所中,年龄≥18 岁且 BMI≥25kg/m²的患者中,有 12%(n=20383)进行了以体重为重点的就诊。20、18 和 19 个站点的 3 个随机序列相似,总体患者平均年龄为 52(SD 16)岁,58%为女性,76%为非西班牙裔白人患者,64%有商业保险,平均 BMI 为 37(SD 7)kg/m²。记录的任何与体重相关的转诊都很少(<6%),共开具了 334 份抗肥胖药物处方。

结论

在大型医疗系统中,年龄≥18 岁且 BMI≥25kg/m²的患者中,有 12%在基线期进行了以体重为重点的就诊。尽管大多数患者有商业保险,但很少有患者转诊到任何与体重相关的服务或开具抗肥胖药物处方。这些结果为尝试改善初级保健中的体重管理提供了依据。

相似文献

1
Baseline Characteristics of PATHWEIGH: A Stepped-Wedge Cluster Randomized Study for Weight Management in Primary Care.PATHWEIGH 研究的基线特征:初级保健中体重管理的阶梯式楔形群随机研究。
Ann Fam Med. 2023 May-Jun;21(3):249-255. doi: 10.1370/afm.2966.
2
PATHWEIGH, pragmatic weight management in adult patients in primary care in Colorado, USA: study protocol for a stepped wedge cluster randomized trial.PATHWEIGH:美国科罗拉多州初级保健中成年患者的实用体重管理:一项阶梯式楔形集群随机试验研究方案。
Trials. 2022 Jan 10;23(1):26. doi: 10.1186/s13063-021-05954-7.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Prelude to PATHWEIGH: pragmatic weight management in primary care.PATHWEIGH 前奏:初级保健中的实用体重管理。
Fam Pract. 2023 Mar 28;40(2):322-329. doi: 10.1093/fampra/cmac092.
5
Access to weight reduction interventions for overweight and obese patients in UK primary care: population-based cohort study.英国初级医疗中为超重和肥胖患者提供减肥干预措施:基于人群的队列研究。
BMJ Open. 2015 Jan 13;5(1):e006642. doi: 10.1136/bmjopen-2014-006642.
6
Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.体重指数对初级保健中体重管理计划的处方成本及潜在成本节约的影响。
J Health Serv Res Policy. 2008 Jul;13(3):158-66. doi: 10.1258/jhsrp.2008.007140.
7
Using implementation facilitation to implement primary care mental health integration via clinical video telehealth in rural clinics: protocol for a hybrid type 2 cluster randomized stepped-wedge design.利用实施促进策略,通过农村诊所的临床视频远程医疗实现初级保健心理健康一体化:混合 2 型集群随机分步楔形设计方案。
Implement Sci. 2019 Mar 21;14(1):33. doi: 10.1186/s13012-019-0875-5.
8
Current approaches to obesity management in UK Primary Care: the Counterweight Programme.英国初级医疗中肥胖管理的当前方法:平衡计划。
J Hum Nutr Diet. 2004 Jun;17(3):183-90. doi: 10.1111/j.1365-277X.2004.00528.x.
9
A new evidence-based model for weight management in primary care: the Counterweight Programme.一种基于证据的基层医疗体重管理新模型:Counterweight项目。
J Hum Nutr Diet. 2004 Jun;17(3):191-208. doi: 10.1111/j.1365-277X.2004.00517.x.
10
Effect of an obesity best practice alert on physician documentation and referral practices.肥胖最佳实践警报对医生记录和转诊实践的影响。
Transl Behav Med. 2017 Dec;7(4):881-890. doi: 10.1007/s13142-017-0514-0.

引用本文的文献

1
Primary care patient and practice member perspectives on weight loss medications: challenges and opportunities.基层医疗患者及医疗机构成员对减肥药物的看法:挑战与机遇
Front Med (Lausanne). 2025 Jul 7;12:1584799. doi: 10.3389/fmed.2025.1584799. eCollection 2025.
2
Electronic health records tools for treating obesity among adult patients in primary care: A scoping review.基层医疗中用于治疗成年肥胖患者的电子健康记录工具:一项范围综述
Obes Pillars. 2025 Jan 19;13:100161. doi: 10.1016/j.obpill.2025.100161. eCollection 2025 Mar.
3
New Insights and Future Directions: The Importance of Considering Poverty in Studies of Obesity and Diabetes.新见解与未来方向:肥胖与糖尿病研究中考虑贫困因素的重要性
Ann Fam Med. 2023 May-Jun;21(3):205-206. doi: 10.1370/afm.2983.

本文引用的文献

1
PATHWEIGH, pragmatic weight management in adult patients in primary care in Colorado, USA: study protocol for a stepped wedge cluster randomized trial.PATHWEIGH:美国科罗拉多州初级保健中成年患者的实用体重管理:一项阶梯式楔形集群随机试验研究方案。
Trials. 2022 Jan 10;23(1):26. doi: 10.1186/s13063-021-05954-7.
2
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.美国开始使用抗肥胖药物患者的处方趋势和临床特征。
Diabetes Obes Metab. 2021 Jul;23(7):1542-1551. doi: 10.1111/dom.14367. Epub 2021 Mar 25.
3
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
4
Determinants and extent of weight recording in UK primary care: an analysis of 5 million adults' electronic health records from 2000 to 2017.英国初级保健中体重记录的决定因素和程度:对 2000 年至 2017 年 500 万成年人电子健康记录的分析。
BMC Med. 2019 Nov 29;17(1):222. doi: 10.1186/s12916-019-1446-y.
5
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.利拉鲁肽的使用与主要心血管事件风险:丹麦和瑞典的基于登记的队列研究。
Lancet Diabetes Endocrinol. 2019 Feb;7(2):106-114. doi: 10.1016/S2213-8587(18)30320-6. Epub 2018 Dec 5.
6
Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity.肥胖症患者 2 型糖尿病与大血管疾病结局的关联:减肥手术的影响。
JAMA. 2018 Oct 16;320(15):1570-1582. doi: 10.1001/jama.2018.14619.
7
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.盐酸氯卡色林对超重和肥胖 2 型糖尿病患者预防和缓解作用的研究(CAMELLIA-TIMI 61):一项随机、安慰剂对照试验。
Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4.
8
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.盐酸氯卡色林在超重或肥胖患者中的心血管安全性。
N Engl J Med. 2018 Sep 20;379(12):1107-1117. doi: 10.1056/NEJMoa1808721. Epub 2018 Aug 26.
9
Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study.有效肥胖症护理的障碍认知:全国行动研究的结果
Obesity (Silver Spring). 2018 Jan;26(1):61-69. doi: 10.1002/oby.22054. Epub 2017 Oct 31.
10
Health Effects of Overweight and Obesity in 195 Countries over 25 Years.25年间195个国家超重和肥胖对健康的影响
N Engl J Med. 2017 Jul 6;377(1):13-27. doi: 10.1056/NEJMoa1614362. Epub 2017 Jun 12.